Ed Anthony Faber , MS, DO

BS: Allegheny College Meadville, PA, 1992 (Biology and Chemistry)

MS: Duquesne University Pit, 1999 (Genetics and Molecular Biology)

DO: Lake Erie College of Osteopathic Medicine Erie, PA, 2003

American Board of Internal Medicine (Hematology) (Certification Date: 11-09-2010 ) - (Recertification Date: to 06-13-2023 )

Hematology and Oncology

Internal Medicine

Medical Oncology

Hematology

Internal Medicine

Medical Oncology

Grant: #M24-108 Investigators:Faber, Edward 06-12-2023 -02-27-2026 AbbVie, Inc. A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma Role:PI 0.00 Hold Level:Industry

Grant: #TAK-573-2001_0021-0680 Investigators:Faber, Edward 07-20-2023 -07-20-2026 Takeda Development Center Americas, Inc. A Study Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With Relapsed Multiple Myeloma Role:PI 2136123.11 Hold Level:Industry

Grant: #P-BCMA-ALLO1-001 Investigators:Faber, Edward 10-30-2023 -10-30-2026 Poseida Therapeutics Open-Label, Multicenter, Phase 1 Study to Assess the Safety ofP-BCMA-ALLO1 in Subjects with Relapsed / Refractory MultipleMyeloma (MM) Role:PI 0.00 Hold Level:Industry

Investigators:Faber, Ed 01-30-2024 -01-30-2027 Poseida Therapeutics Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects with Selected Relapsed/Refractory B cell Malignancies Role:PI 519385.54 Hold Level:Industry

Grant: #R01CA279962 JIT Investigators:Desai, Pankaj; Faber, Ed; Kotagiri, Nalinikanth; Sertorio, Mathieu; Xie, Changchun 12-01-2023 -11-30-2028 National Cancer Institute Genetically-encoded molecular imaging of genome-edited immune cells Role:Collaborator 0.00 Hold Level:Federal

Grant: #M22-574 Investigators:Faber, Ed 09-23-2024 -09-23-2027 AbbVie, Inc. A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared with Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study) Role:PI 1325993.12 Hold Level:Industry

Investigators:Faber, Ed 11-15-2024 -11-15-2027 Kite Pharma, Inc. A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Role:PI 1475078.65 Hold Level:Industry